ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

PRO-169

A development code.

Its studies are led by Laboratorios Sophia S.A de C.V.

Furthest: phase 1, since Feb 17, 20261 company-led study, 1 open or runningNext primary completion: Dec 15, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laboratorios Sophia S.A de C.V.11 open or runningphase 1since Feb 17, 2026Feb 17, 2026Dec 15, 2026phase 1 · NCT07429474

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2026First study: phase 1 study in ImmunogenicityFirst studyNCT07429474 · 60 planned · Mexico

Ahead

  1. Dec 15, 2026Primary completion: phase 1 study in ImmunogenicityNCT07429474

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07429474Immunogenicity · Mexico1Not yet recruitingDec 15, 202660

How it is read

Names in the registry

  • “PRO-169”, 1 entry

Codes read as this program: PRO169.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.